Highest-materiality recent filing
Xeris Biopharma exchanges ~69% of 8% Convertible Notes due 2028 for cash and stock
Entered private exchange to retire ~$23M (69%) of 8% Convertible Senior Notes due 2028.
Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.
Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.
Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance
Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.
Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application
Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.
Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M
Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).
Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M
Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).
Xeris unveils long-range strategy; targets ~$750M revenue by 2030
Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.
Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M
Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.
Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M
Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)
Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).
Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M
Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).
Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.
Xeris Biopharma promotes Kevin McCulloch to President and COO
Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.
Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)
CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.
Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M
Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).
Xeris reports Q4 total revenue $44.4M (+34% YoY); refinances debt with $200M Hayfin facility
Q4 total revenue $44.4M, +34% YoY; full-year 2023 revenue $163.9M, +49% YoY.
Xeris expects Q4 cashflow positive, 2023 revenue at high end of $160M-$165M
Total revenue for FY 2023 expected at high end of prior $160M-$165M guidance.
Record Q3 revenue $48.3M (+63% YoY); tightens FY23 guidance to $160-165M
Total revenue $48.3M, up 63% YoY and 27% QoQ; product revenue $41.7M, up 41% YoY.
Xeris raises year-end cash guidance to $65-70M, tightens 2023 revenue to $155-165M
Year-end cash, equivalents, and short-term investments guided to $65-70M (up from $55-65M).
Xeris exchanges $32M of 5% 2025 notes for $33.6M of 8% 2028 notes; extends debt maturity
Exchanged $31,975,000 of 5% convertible notes due 2025 for $33,574,000 of 8% notes due July 2028.
Xeris Q2 revenue $38.0M record, up 50% YoY; tightens FY23 guidance upward
Record total revenue $38.0M, QoQ +14%, YoY +50%; product revenue $36.9M (+46%).
Xeris Q1 revenue $33.2M (+50% YoY); reaffirms 2023 guidance
Total revenue $33.2M vs $22.1M in Q1 2022; Gvoke net revenue $15.0M (+21%), Keveyis $12.8M (+37%), Recorlev $4.5M.
Q4 net product revenue $32.5M, up 52% YoY; full-year 2022 net product revenue $109.3M, up 38% pro forma.
Xeris expects 2022 net product revenue at top of $105M-$110M guidance, cash >$120M
Expects 2022 net product revenue at top of guidance range of $105M-$110M.
Xeris Biopharma Q3 product revenue $29.6M, record; raises cash guidance to $110-120M
Net product revenue $29.6M, up 31% pro forma YoY; Gvoke $13.7M (+24%), Keveyis $13.4M, Recorlev $2.5M.
Xeris reports positive Phase 1 data for SC levothyroxine (XP-8121); weekly dosing matches daily oral
Phase 1 study (n=60) shows proof-of-concept for once-weekly SC XP-8121 with steady-state exposure similar to daily oral Synthroid.
Xeris Biopharma Q2 net product revenue record $25.3M, reaffirms FY guidance
Record Q2 net product revenue $25.3M, up 15% from Q1 and 34% pro forma YoY.
Xeris Q1 net product revenue $21.9M (+33% pro forma); net loss $33.7M; reaffirms FY22 guidance
Q1 net product revenue $21.9M, up 33% pro forma vs prior year; net loss $33.7M ($0.25/share).
Xeris drew $100M from new $150M Hayfin term loan (9%+SOFR, warrants at $2.28, 5-yr maturity); repaid $43.5M Oxford/SVB debt.
Xeris Biopharma raises $30M in private placement with Armistice Capital
Gross proceeds of $30M from sale of 10.2M shares at $2.93/share (closing price Dec 31, 2021).
On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.
On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.
On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.
The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.
On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.
On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.
John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.
On March 29, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) announced the expansion of the Company’s Board of Directors (the "Board") from 8 to 9 members and the appointment of Ricki Fairley to the Board on March 27, 2023.
each of the following members of the Xeris board of directors was designated and appointed to the Board: BJ Bormann, Ph.D., Dawn Halkuff, Marla S. Persky, John Schmid and Jeffrey W. Sherman, M.D., FACP
Max materiality 0.85 · Median 0.70 · Most common event earnings